Articlenpj drug discovery2026
Diversity Beats Size Scaling for Chemical Language Models.
Article in npj drug discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemical language models, such as transformers trained on SMILES strings, are increasingly used in drug design and have seen rapid growth in both model capacity and training dataset size. The impact of this scaling on practical downstream performance remains unclear, however. We systematically evaluate how model size and dataset size affect encoder-decoder transformers trained on paired textual molecular representations. We find that, beyond a minimal threshold, further model scaling yields no gain in hit generation rate, while dataset scaling gives diminishing returns. We further introduce a dataset diversification strategy that substantially increases hit diversity. These results suggest that, for molecular hit discovery, data curation and diversity may be more impactful than continued scaling of model size or dataset volume, and they motivate a shift from scale-first to diversity-first training paradigms.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.